Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .


These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external video platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name Youtube
Purpose External media


We are thankful to our funding agencies for their support:

Deutsche Krebshilfe


A MultIceNTer PhasE I RNA VaCcine Trial to Exploit NeoePitope-Specific T Cells for the Treatment of H3K27M-Mutated Gliomas – (INTERCEPT H3). 2019 - 2023

Regulation of tumor immunity through the integrated stress response (ISR) in myeloid cells. 2019 - 2021



Helmholtz Gemeinschaft


Helmholtz Zukunftsthema Immunologie und Infektion, WP3: Innovative Therapies. 2017 - 2020

Else Kröner-Fresenius-Stiftung


Mechanismen hirntumorreaktiver T-Helferzellen im Kontext immuntherapeutischer Interventionen. 2019 - 2021

Imaging von Immunantworten und Tumorzellinvasion in Gliom Modellen. 2019 - 2021

Deutsches Konsortium für Translationale Krebsforschung

TCR Proof of Concept in cooperation with NCT (TCR-POC)

AMPLIFYing NEOepitope-specific VACcine Responses in progressive diffuse glioma – a randomized, open label, 3 arm multicenter Phase I trial (AMPLIFY-NEOVAC, NOA-21)

Targeting IDH1R132H in WHO grade III-IV IDH1R132H-mutated gliomas by a peptide vaccine - a Phase I safety, tolerability and immunogenicity multicenter trial (NOA-16)

CAR2Brain_Immune Response CAR-NK Immunotherapy in Glioblastoma_DKTK Joint Funding “UPGRADE”. 2020 - 2024

Baden Württemberg Stiftung


REsolvInG ImmuNITy to targEt Brain Tumors (RE-IGNITE). 2020 - 2023

Deutsche Forschungsgemeinschaft


Understanding and targeting resistance in glioblastoma. CRC UNITE 1389. 2019 - 2023

Vascular control of tumor immunity in the CNS. CRC1366. 2019 - 2022

Hallmarks of Skin Cancer, Tumor Microenvironment and Melanoma Immunity, Response and Resistance to Checkpoint Blockade in melanoma brain metastases. CRC RTG2099. 2019 - 2024

Impact of dietary tryptophan on the gut microbiome and autoimmune neuroinflammation. 2018 - 2020. 

Schwiete Stiftung


Maßgeschneiderte Immuntherapie von Patienten mit Hirntumoren. 2017 - 2020



The role of CXCL10 in the immune regulation of melanoma and glioma. 2019 - 2022

Swiss Cancer League, the Swiss Cancer Research foundation and the Union for International Cancer Control (UICC)


Swiss Bridge Award 2019 - Rational design of inhibitory chimeric antigen receptor (iCAR) to prevent anti CD19 CAR-T cell related neurotoxicity in B-cell malignancies. 2019 - 2022

Hertie Stiftung


Hertie Academy of clinical neuroscience als Kristallisationspunkt für ein Hertie Network of Excellence in clinical neuriscience. 2019 - 2022

to top
powered by webEdition CMS